Q2 FY26 results: standalone revenue dips, consolidated grows 25.6% YoY
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts less than Nifty Microcap 250 and 3.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited Q2 FY26 and H1 FY26 results on 19 Dec 2025. Standalone Q2 revenue fell about 17% YoY to Rs.8,788 lakhs, PAT at Rs.2,974 lakhs. Consolidated H1 revenue grew 25.6% to Rs.28,758 lakhs, PAT up about 18.5% to Rs.7,805 lakhs. First listed results post Nov 2025 IPO at Rs.593 per share. Auditor BSR gave an unqualified limited review.
Mixed first post-listing print: strong consolidated growth from subsidiaries and recent acquisition, while standalone quarter dipped. Sets baseline for tracking as a newly listed stock.